NCT06607185 2026-04-22A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid TumorsEli Lilly and CompanyPhase 1 Active not recruiting750 enrolled
NCT06447662 2026-04-20A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.PfizerPhase 1 Recruiting330 enrolled
NCT07458347 2026-04-15A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) MutationKestrel Therapeutics, Inc.Phase 1 Recruiting145 enrolled
NCT02465060 2026-04-13Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)National Cancer Institute (NCI)Phase 2 Active not recruiting6,452 enrolled 2 FDA
NCT05462717 2026-04-08Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid TumorsRevolution Medicines, Inc.Phase 1 Active not recruiting222 enrolled
NCT05983133 2026-04-07A Study of PF-08046052/SGN-EGFRd2 in Advanced Solid TumorsSeagen Inc.Phase 1 Active not recruiting68 enrolled